Cost-effectiveness analysis of bevifibatide for patients with acute coronary syndrome undergoing percutaneous coronary intervention in China

Read full text Summarise with VIRAT
Authors: Kaijie Yao, Yun Bao, Ying Chen, Yan Zhong, Mengxia Yan, Wen Li, Bin Wu
Cited by: 0
References: 19

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

This study evaluated the cost-effectiveness of bevifibatide versus eptifibatide for acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) in China. A 30-day decision tree and 15-year Markov model simulated outcomes using matching-adjusted indirect comparison data. Base-case analysis used current listed price of bevifibatide (¥1290/vial). Costs and quality-adjusted life-years (QALYs) were evaluated against willingness-to-pay (WTP) thresholds based on China's per capita gross domestic product (GDP). Base-case results showed bevifibatide added ¥12,909.24 and 0.0595 QALYs, yielding an incremental cost-effectiveness ratio (ICER) of ¥216,899/QALY. This significantly exceeds the ¥76,599 WTP threshold (0.8 times GDP), indicating it is not cost-effective. Lifetime analysis confirmed these results (ICER: ¥159,541/QALY). Threshold analysis indicated a price reduction to approximately ¥595/vial is required to achieve cost-effectiveness. In conclusion, bevifibatide is not cost-effective for ACS patients undergoing PCI in China at its current price. A substantial price reduction is necessary to align cost with clinical value, providing an evidence-based threshold for future reimbursement negotiations.

Fields of Study & Subjects

Health Systems Economic Evaluations Quality of Life Coronary Interventions and Diagnostics Antiplatelet Therapy and Cardiovascular Diseases

Publication details

Journal / source
Pharmacoeconomics and Policy
Volume
2
Issue
1
Pages
46–53
Publication date
1 March 2026
Language
EN